Discover

YMAB
Y-mAbs Therapeutics, Inc.
8.61
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
Ytd
1y
8.61
day range
8.61
3.55
52 week range
16.11
Open8.61Prev Close8.61Low8.61High8.61Mkt Cap391.22M
Vol760.68KAvg Vol905.07KEPS-0.50P/E-17.22Forward P/E-13.98
Beta0.67Short Ratio13.91Inst. Own72.19%DividendN/ADiv YieldN/A
Ex Div DateN/AEarningN/A50-d Avg6.84200-d Avg6.121yr Est20.64

YMAB News

Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?
zacks.com
Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?

After reaching an important support level, Y-mAbs Therapeutics, Inc. (YMAB) could be a good stock pi

Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
globenewswire.com
Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, L

NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisian

Deal Dispatch: Performance Food Group And Claire's Lead A Week Of Big Auctions, Retail Woes
benzinga.com
Deal Dispatch: Performance Food Group And Claire's Lead A Week Of Big Auctions, Retail Woes

Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire'

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.07 per share versus the Zacks

Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders
businesswire.com
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breac

Y-mAbs (YMAB) Q2 Revenue Falls 14%
fool.com
Y-mAbs (YMAB) Q2 Revenue Falls 14%

Y-mAbs Therapeutics (YMAB), a biopharmaceutical company focused on developing and commercializing an

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
globenewswire.com
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mA

benzinga.com
Earnings Scheduled For August 8, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)
prnewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc.

NEW YORK , Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Ass

Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
businesswire.com
Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, L

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
globenewswire.com
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mA

YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
zacks.com
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?

YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher

Y-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley
https://thefly.com
Y-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley

Morgan Stanley upgraded Y-mAbs Therapeutics to Equal Weight from Underweight with a price target of

Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord
https://thefly.com
Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord

Canaccord downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $2

Y-mAbs Therapeutics downgraded to Perform from Outperform at Oppenheimer
https://thefly.com
Y-mAbs Therapeutics downgraded to Perform from Outperform at Oppenheimer

Oppenheimer analyst Jeff Jones downgraded Y-mAbs Therapeutics without a price target to Perform from

Y-mAbs Therapeutics downgraded to Hold from Buy at Brookline
https://thefly.com
Y-mAbs Therapeutics downgraded to Hold from Buy at Brookline

Brookline analyst Kemp Dolliver downgraded Y-mAbs Therapeutics to Hold from Buy with an $8.60 price

Y-mAbs Therapeutics downgraded to Hold from Buy at Truist
https://thefly.com
Y-mAbs Therapeutics downgraded to Hold from Buy at Truist

Truist downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $14,

Shareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
prnewswire.com
Shareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair

MILWAUKEE , Aug. 5, 2025 /PRNewswire/ -- The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for p

YMAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Y-mAbs Therapeutics, Inc. Is Fair to Shareholders
businesswire.com
YMAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Y-mAbs Therapeutics, Inc. Is

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t

SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
globenewswire.com
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

Acquisition to Include Naxitamab-gqgk DANYELZA ® ( Naxitamab-gqgk) , Further Broadening SERB's Rare

YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know
zacks.com
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know

YmAbs Therapeutics (YMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab

benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga.com
Earnings Scheduled For May 13, 2025

benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

benzinga.com
Earnings Scheduled For March 4, 2025

benzinga.com
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Sessio

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-q

benzinga.com
Earnings Scheduled For February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings

benzinga.com
Earnings Scheduled For November 13, 2023

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its

benzinga.com
Earnings Scheduled For August 10, 2023

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl

benzinga.com
Earnings Scheduled For May 8, 2023

Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 pe

benzinga.com
Earnings Scheduled For March 30, 2023

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quart

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 469 companies hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  On Thursday, 175 stocks hit new 52-week lows.

benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023

benzinga.com
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday

Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique

benzinga.com
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on M

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  During Monday's session, 96 stocks hit new 52-week lows.

benzinga.com
Why Global Payments Shares Are Trading Lower By Around 8%? Here Are 41 Stocks Moving In Monday's Mid

Gainers 1847 Holdings LLC (NASDAQ: EFSH) shares surged 72.7% to $3.25 after the company reported

benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Upgrades

benzinga.com
Earnings Scheduled For August 8, 2022

  Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings fo

benzinga.com
Earnings Scheduled For May 9, 2022

  Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quar

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

    During Wednesday's morning trading, 400 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  During Friday's session, 445 companies made new 52-week lows.

benzinga.com
Earnings Scheduled For November 4, 2021

  Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e

benzinga.com
Earnings Scheduled For August 5, 2021

  Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report q

benzinga.com
70 Biggest Movers From Friday

Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday.

benzinga.com
Earnings Scheduled For May 6, 2021

  Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly e

benzinga.com
Earnings Scheduled For February 25, 2021

  Companies Reporting Before The Bell • PG&E (NYSE:PCG) is likely to report quarterly earnings

benzinga.com
Stocks That Hit 52-Week Highs On Monday

  During Monday's morning session, 460 companies made new 52-week highs.

benzinga.com
Earnings Scheduled For November 5, 2020

  Companies Reporting Before The Bell • Bluerock Residential Growth REIT, Inc. Class A Common Stoc